1. Introduction

Cross-Border Biotech Mergers Regulation refers to the legal framework governing mergers, acquisitions, amalgamations, takeovers, joint ventures and corporate restructuring involving biotechnology companies situated in different countries.

The regulation becomes particularly important when a multinational pharmaceutical or biotechnology company acquires another enterprise engaged in:

Genetic engineering and genome editing.

CRISPR technology and gene therapies.

Biotechnology research and development.

Pharmaceutical and vaccine manufacturing.

Genomic sequencing and genetic databases.

Stem-cell research and regenerative medicine.

Artificial intelligence-based drug discovery.

Synthetic biology and biological manufacturing.

Agricultural biotechnology and genetically modified organisms.

Biobanks and biological sample repositories.

Unlike ordinary commercial mergers, biotechnology mergers can affect public health, genetic privacy, biological resources, scientific research, national security, competition and access to essential medicines.

Consequently, a cross-border biotech merger may require approval from several regulatory authorities simultaneously, including competition regulators, foreign investment authorities, pharmaceutical regulators, biosafety authorities, intellectual property offices and data protection authorities.

Central legal principle: A merger that is legally valid under the corporate law of one country may still be prohibited, restricted or made conditional by another country because of its effects on competition, national security, public health or biological resources.

2. Objectives of cross-border biotech merger regulation

The principal objectives are:

Competition protection: Prevent monopolisation of biotechnology markets and excessive concentration of genetic technologies.

Public health protection: Ensure that mergers do not restrict access to vaccines, medicines, diagnostic tests and life-saving therapies.

National security: Prevent unauthorised foreign control over sensitive biological technologies and strategically important research.

Genetic-data protection: Prevent improper transfer, exploitation or commercialisation of genetic and genomic information.

Intellectual property protection: Protect patents, trade secrets, research licences and biotechnology inventions.

Biosafety: Ensure that mergers do not weaken biological containment, laboratory safety or GMO regulation.

Research independence: Protect scientific research, clinical trials and independent biotechnology institutions.

Regulatory accountability: Ensure that multinational enterprises comply with the laws of every jurisdiction in which they operate.

3. International legal framework

There is no single universal treaty governing all cross-border biotechnology mergers. Instead, several international legal instruments influence their regulation.

A. TRIPS Agreement

The Agreement on Trade-Related Aspects of Intellectual Property Rights establishes minimum international standards for intellectual property protection.

Its provisions are relevant when a foreign biotechnology company acquires:

Patented gene-editing technology.

Pharmaceutical formulations.

Genetically engineered microorganisms.

Biotechnological manufacturing processes.

Diagnostic technologies.

Proprietary research platforms.

Articles 27, 28 and 39 are particularly relevant to patent protection and undisclosed information.

A merger cannot automatically extinguish existing intellectual property rights or eliminate applicable licensing obligations.

B. Cartagena Protocol on Biosafety

The Cartagena Protocol is relevant where a merger involves companies handling living modified organisms.

It establishes an international biosafety framework for the transboundary movement, handling and use of living modified organisms.

A foreign acquisition of a biotechnology enterprise may therefore require reassessment of:

Biosafety management systems.

GMO transport arrangements.

Laboratory containment procedures.

Environmental risk assessments.

Biological material transfer agreements.

C. Nagoya Protocol

The Nagoya Protocol becomes relevant when the acquired company possesses genetic resources obtained from another country.

The transaction may involve access-and-benefit-sharing obligations, prior informed consent and mutually agreed terms, depending on the applicable national access-and-benefit-sharing legislation.

For example, acquiring a company holding microbial strains, medicinal plant samples or indigenous biological material does not necessarily transfer unrestricted rights to exploit those resources commercially.

4. Regulatory framework in India

India is particularly important in cross-border biotechnology mergers because of its pharmaceutical manufacturing industry, agricultural biotechnology, genetic research, vaccine production and developing biotechnology sector.

Several laws operate simultaneously.

A. Competition Act, 2002

The Competition Act, 2002 is the principal legislation governing merger control in India.

The Competition Commission of India (CCI) examines whether a proposed combination is likely to cause an appreciable adverse effect on competition (AAEC) in the Indian market.

Important provisions include:

Extra-territorial jurisdiction under Section 32

This provision is particularly significant for cross-border biotechnology transactions.

Even when both merging companies are incorporated outside India, the CCI may examine the transaction if it has, or is likely to have, an appreciable adverse effect on competition in the relevant Indian market.

For instance, a foreign acquisition involving two international producers of CRISPR technologies could attract Indian competition scrutiny if the transaction substantially affects the supply, licensing or availability of those technologies in India.

The CCI's official combination framework explains the notification and assessment system.

CCI+1

B. Deal-value threshold

The Competition (Amendment) Act, 2023 introduced the deal-value threshold into India's merger-control system.

A transaction exceeding ₹2,000 crore in deal value may require notification where the target enterprise has substantial business operations in India, subject to the applicable statutory provisions and exemptions.

This is particularly relevant to biotechnology acquisitions because an emerging genomics or drug-discovery enterprise may have valuable technology, patents, databases or research assets despite relatively low conventional turnover.

The deal-value threshold helps address acquisitions of innovative companies whose competitive significance is not reflected adequately in their current revenue.

C. Foreign Exchange Management Act, 1999

The FEMA framework regulates cross-border investment and financial transactions.

Important considerations include:

Foreign investment in Indian biotechnology companies.

Acquisition of shares by non-resident investors.

Payment of consideration to foreign shareholders.

Valuation of shares and assets.

Reporting requirements.

Repatriation of investment proceeds.

Compliance with applicable FDI policy restrictions.

The parties must separately examine whether the investment route is automatic or requires government approval.

D. Foreign investment and national security

A foreign acquisition involving biotechnology research, sensitive biological information or strategically important manufacturing may require examination under India's foreign investment policy and applicable security-related restrictions.

Particular attention may be necessary where the transaction involves:

Genetic databases.

Strategic vaccine manufacturing.

Sensitive pathogen research.

Biological defence-related technology.

Critical pharmaceutical supply chains.

E. Biological and biotechnology regulation

The following legislation may become relevant depending on the activities of the acquired company:

Environment (Protection) Act, 1986.

Rules, 1989, concerning the manufacture, use, import, export and storage of hazardous microorganisms and genetically engineered organisms or cells.

Biological Diversity Act, 2002, as amended.

Patents Act, 1970.

Drugs and Cosmetics Act, 1940, and applicable rules.

New Drugs and Clinical Trials Rules, 2019.

Digital Personal Data Protection Act, 2023, to the extent applicable and brought into force.

Information Technology Act, 2000, and applicable rules.

The merger agreement must account for existing licences, approvals, biological material restrictions, clinical-trial obligations and environmental liabilities.

F. Foreign Exchange Management (Cross Border Merger) Regulations, 2018

These RBI regulations specifically govern inbound and outbound mergers involving Indian and foreign companies.

They address:

Transfer of securities and assets.

Foreign liabilities and borrowings.

Overseas subsidiaries.

Valuation and consideration.

Compliance with foreign investment requirements.

Treatment of assets and liabilities following the merger.

For example, if an American biotechnology company merges with an Indian pharmaceutical research company, the resulting corporate structure must comply with the applicable FEMA cross-border merger requirements, in addition to company-law and competition-law approvals.

LTNR+1

5. European Union regulatory framework

The European Union has a sophisticated merger-control system that can apply even when both merging companies are incorporated outside Europe.

A. EU Merger Regulation, 2004

Council Regulation (EC) No. 139/2004 governs concentrations between undertakings.

Its important provisions include:

Article 1: Community dimension and jurisdictional thresholds.

Article 2: Substantive assessment of concentrations.

Article 3: Definition of concentration.

Article 6: Preliminary examination.

Article 8: Final decisions.

Article 22: Referral of concentrations by Member States.

Article 21: Exclusive jurisdiction in matters covered by the Regulation, subject to its provisions.

The European Commission examines whether a merger significantly impedes effective competition, particularly through the creation or strengthening of a dominant position.

The EU rules expressly cover qualifying mergers irrespective of the location of the companies' registered offices.

European Commission

B. Biotechnology-specific competition concerns

EU authorities may examine whether a merger:

Eliminates an important biotechnology research competitor.

Restricts access to genetic sequencing platforms.

Reduces competition in cancer diagnostics.

Prevents rival pharmaceutical companies from accessing essential technology.

Concentrates control over gene-editing patents.

Reduces innovation in pharmaceutical development.

C. EU Foreign Subsidies Regulation

Regulation (EU) 2022/2560 may also become relevant where foreign financial contributions distort competition in the EU internal market, including in certain acquisition and merger transactions.

It provides an additional regulatory layer beyond conventional merger control.

6. United States regulatory framework

The United States applies multiple regulatory systems to cross-border biotechnology mergers.

A. Hart-Scott-Rodino Antitrust Improvements Act, 1976

The HSR Act establishes pre-merger notification requirements for qualifying transactions.

The Federal Trade Commission (FTC) and Department of Justice (DOJ) examine whether acquisitions may substantially lessen competition or tend to create a monopoly.

Biotechnology acquisitions are particularly sensitive where the acquiring company controls:

Pharmaceutical patents.

Genetic sequencing infrastructure.

Clinical research platforms.

Biological manufacturing facilities.

Essential diagnostic technologies.

B. Federal Trade Commission Act

Section 7 of the Clayton Act prohibits acquisitions whose effect may substantially lessen competition or tend to create a monopoly.

Section 5 of the FTC Act also provides an enforcement framework against unfair methods of competition.

C. CFIUS and biotechnology national security

The Committee on Foreign Investment in the United States (CFIUS) reviews certain foreign investments and transactions involving US businesses.

Biotechnology transactions can attract scrutiny where they involve sensitive personal data, critical technologies or other national-security concerns.

For example, acquisition of a US genomics company by a foreign enterprise may raise concerns involving access to genetic information, sensitive biological research or strategically important technologies.

D. FDA regulatory considerations

The Food and Drug Administration (FDA) regulates relevant drugs, biological products, medical devices and clinical research activities.

An acquisition does not automatically transfer every regulatory permission without qualification. The parties must assess applicable reporting, registration, licence and manufacturing obligations.

They must also preserve compliance with clinical-trial requirements, product safety obligations and manufacturing standards.

7. Australia regulatory framework

Australia provides another important comparative jurisdiction for biotechnology mergers.

The principal legal frameworks include:

A. Australian Competition and Consumer Commission

The ACCC examines acquisitions that may substantially lessen competition.

An acquisition involving a major biotechnology manufacturer may raise concerns about reduced competition in vaccines, genetic testing, pharmaceuticals or agricultural biotechnology.

Important current development: Australia's mandatory merger-control regime commenced on 1 January 2026. Qualifying acquisitions must be notified to the ACCC and cannot proceed before the required approval.

ACCC

B. Foreign investment screening

The Foreign Investment Review Board (FIRB) framework is relevant when foreign investors acquire Australian biotechnology businesses.

The assessment may consider:

National security.

Critical technologies.

Sensitive biological information.

Research infrastructure.

Strategic pharmaceutical manufacturing.

Public-interest considerations.

C. Gene technology compliance

A merger involving a company licensed to conduct dealings with genetically modified organisms must account for applicable obligations under the Gene Technology Act 2000.

Corporate restructuring cannot be treated as an exemption from biosafety compliance.

The continuing entity must establish that applicable licences, approvals and regulatory responsibilities remain properly addressed.

8. Important judicial decisions and case laws

The following cases are especially significant because they demonstrate how competition law, biotechnology innovation, foreign acquisition and regulatory jurisdiction interact.

Case 1. Illumina Inc. v European Commission and Grail LLC v European Commission (2024)

Leading biotechnology merger jurisdiction case

Citation: Joined Cases C-611/22 P and C-625/22 P, ECLI:EU:C:2024:677, judgment dated 3 September 2024.

Facts:

Illumina, a US biotechnology company specialising in genetic sequencing technology, proposed acquiring Grail, another US company developing blood tests for early cancer detection.

The transaction raised concerns regarding competition in genetic sequencing and cancer diagnostics.

Although the transaction did not satisfy the EU Merger Regulation's conventional EU-wide turnover thresholds, the European Commission accepted referrals from national competition authorities under Article 22.

Illumina challenged the Commission's jurisdiction.

Legal issue:

Could the European Commission accept an Article 22 referral from a national competition authority that lacked competence to examine the transaction under its own national merger-control laws?

Judgment:

The Court of Justice of the European Union ruled against the Commission's interpretation.

It held that the Commission could not accept an Article 22 referral from a national competition authority that was not competent under its national law to examine the proposed concentration.

The Court set aside the General Court's earlier judgment and annulled the Commission's referral decisions.

Legal principles:

Merger-control jurisdiction must have a proper legal foundation.

Competition authorities cannot exercise unlimited jurisdiction over foreign acquisitions.

Legal certainty is an essential requirement of merger regulation.

Biotechnology innovation does not eliminate statutory jurisdictional limits.

Regulatory intervention must remain within the authority granted by legislation.

Importance:

This is an extremely important precedent for cross-border biotechnology acquisitions involving emerging technologies and companies with little or no conventional turnover.

curia+2

Case 2. FTC v. Illumina, Inc. (2023)

Citation: 88 F.4th 103 (5th Cir. 2023).

Facts:

Illumina's acquisition of Grail was also examined by US competition authorities.

The FTC was concerned that Illumina could restrict access to genetic sequencing services needed by competing developers of multi-cancer early detection tests.

Legal issue:

Could a vertical merger between a supplier of an important technology and a downstream biotechnology company substantially lessen competition?

Decision:

The US Court of Appeals for the Fifth Circuit upheld the FTC's decision requiring divestiture, finding sufficient support for the competition concerns.

Legal principles:

Vertical mergers can create competition concerns even when the parties operate at different levels of a supply chain.

Control over an essential input may allow an acquiring company to disadvantage downstream competitors.

Innovation markets must be considered in merger assessment.

Potential foreclosure of competing biotechnology developers is a relevant competition concern.

Importance:

The case illustrates why regulators examine not merely market shares but also access to scientific infrastructure and essential research technologies.

Case 3. CCI – Bayer AG / Monsanto Company (2018)

Important Indian biotechnology merger precedent

Authority: Competition Commission of India.

Facts:

German pharmaceutical and life-sciences company Bayer proposed acquiring Monsanto, a multinational company engaged in seeds, agricultural biotechnology and crop-protection products.

The transaction raised competition concerns in several Indian markets.

The CCI examined the effect of the acquisition on:

Agricultural biotechnology.

Genetically modified crop traits.

Cotton seeds.

Corn seeds.

Vegetable seeds.

Herbicides.

Access to proprietary agricultural technology.

Legal issue:

Would the acquisition create an appreciable adverse effect on competition in Indian agricultural biotechnology markets?

Decision:

On 20 June 2018, the CCI approved the transaction subject to modifications.

The remedies included divestiture of specified businesses and assets, including:

Glufosinate ammonium business.

Cotton and corn crop traits.

Hybrid vegetable seed business.

Monsanto's 26% shareholding in Maharashtra Hybrid Seed Company Limited.

The CCI also imposed licensing commitments requiring broad-based, non-exclusive licensing of specified GM and non-GM traits on fair, reasonable and non-discriminatory terms for seven years.

Legal principles:

A global merger can have substantial effects in the Indian domestic market.

Control over agricultural biotechnology technology can create competition concerns.

Divestiture can be used to restore competitive market conditions.

Licensing remedies can protect access to essential biotechnology innovations.

Competition authorities may impose behavioural and structural remedies together.

Importance:

This is one of the most relevant Indian precedents for cross-border mergers involving biotechnology, agricultural research and proprietary genetic technologies.

Press Information Bureau+1

Case 4. European Commission – Bayer/Monsanto (2018)

Citation: Case M.8084 – Bayer/Monsanto, Commission Decision of 21 March 2018.

Facts:

Bayer proposed acquiring Monsanto, combining two major international businesses in agricultural chemicals, seeds and biotechnology.

The European Commission investigated potential competition concerns.

Legal issue:

Would the proposed acquisition reduce competition in agricultural seeds, crop protection and biotechnology innovation?

Decision:

The Commission approved the acquisition subject to extensive commitments, including divestitures designed to preserve competition.

BASF acquired significant divested businesses and assets.

Legal principles:

Mergers must be examined across overlapping product and innovation markets.

Divestiture remedies must be sufficient to create or preserve a viable competitor.

Research and development competition can be relevant independently of existing product-market competition.

Global mergers may require coordinated remedies in multiple jurisdictions.

Importance:

The case demonstrates the use of structural remedies in international agricultural biotechnology transactions.

EUR-Lex+1

Case 5. European Commission – Dow/DuPont (2017)

Citation: Case M.7932 – Dow/DuPont, Commission Decision of 27 March 2017.

Facts:

Dow Chemical and DuPont proposed a major combination involving agricultural chemicals, seeds and biotechnology-related research.

The Commission identified concerns regarding competition in crop-protection products and innovation.

Legal significance:

The Commission required substantial divestiture commitments, including research and development-related assets, to address identified competition concerns.

Principles established:

Innovation competition is a relevant consideration in merger control.

Potential future products must be considered where evidence supports their competitive significance.

A merger may harm competition even when immediate consumer prices are not expected to increase.

Research capabilities can be important components of an effective divestiture remedy.

Importance:

The decision is particularly relevant to mergers involving gene-editing research, agricultural biotechnology and pharmaceutical research pipelines.

9. Major legal issues in cross-border biotech mergers

A. Anti-competitive concentration

One of the most important concerns is the creation of a dominant biotechnology enterprise.

For example, if two companies controlling a substantial proportion of the global CRISPR market merge, the resulting enterprise may obtain excessive control over:

Gene-editing patents.

Research equipment.

Licensing arrangements.

Clinical research infrastructure.

Biotechnology manufacturing.

Access to essential scientific data.

Competition regulators may prohibit the transaction or impose conditions.

B. Transfer of genetic and genomic information

Biotechnology companies frequently possess highly sensitive information, including:

Human DNA sequences.

Genetic disease information.

Family genetic histories.

Clinical-trial participant information.

Genomic research databases.

Biological sample records.

A cross-border merger may transfer control over these databases to a foreign company.

The acquiring company must assess the applicable privacy, consent, cybersecurity, confidentiality and international data-transfer requirements.

In India, the Digital Personal Data Protection Act, 2023, is relevant to the extent its provisions and applicable rules have commenced and apply to the information concerned.

C. Transfer of biological resources

A merger may involve the transfer of:

Microorganism collections.

Human biological samples.

Plant genetic resources.

Indigenous biological materials.

Cell lines.

Genetically modified organisms.

Such transfers may trigger access-and-benefit-sharing obligations under applicable domestic legislation implementing the Convention on Biological Diversity and Nagoya Protocol.

In India, the Biological Diversity Act, 2002, as amended, is particularly important.

D. Intellectual property and patent ownership

Biotechnology mergers frequently involve complicated intellectual property arrangements.

Important issues include:

Ownership of existing biotechnology patents.

Transferability of exclusive licences.

Patent validity disputes.

Ownership of jointly developed inventions.

Research collaboration agreements.

Trade-secret protection.

Patent infringement litigation.

Compulsory licensing and public-health obligations.

A foreign acquisition must also consider the patent laws of countries where the acquired technology is protected or commercialised.

E. Clinical-trial continuity

Where the acquired company conducts clinical trials, the merger must not compromise participant protection.

The parties must examine:

Existing clinical-trial authorisations.

Ethics committee approvals.

Informed-consent documentation.

Adverse-event reporting.

Clinical-trial insurance.

Research data integrity.

Sponsor responsibilities.

Long-term monitoring obligations.

A change in corporate ownership does not automatically eliminate the obligations arising from ongoing clinical research.

F. National security and strategic biotechnology

Biotechnology has increasing strategic importance.

Foreign acquisition of enterprises developing synthetic biology, advanced vaccines, genomic sequencing or pathogen-related technologies may attract national-security scrutiny.

Regulators may examine whether the acquisition could create risks involving:

Biological security.

Sensitive research.

Strategic manufacturing capacity.

Access to critical genetic databases.

Dependence on foreign suppliers.

Dual-use biological technologies.

G. Environmental and biosafety liability

An acquiring company may inherit or become responsible for environmental and regulatory liabilities associated with the acquired business.

Examples include:

GMO contamination.

Laboratory containment failures.

Improper disposal of biological waste.

Accidental release of genetically modified organisms.

Unauthorised biological material transfers.

Historical environmental damage.

The merger agreement should therefore contain appropriate representations, warranties, indemnities and environmental liability provisions.

10. Regulatory approval procedure for cross-border biotech mergers

The regulatory process generally involves several stages.

Transaction planning

Identify the acquiring company, target company, countries involved, ownership structure and biotechnology activities.

Competition assessment

Determine whether merger notification is required in India, the EU, the US, Australia and other relevant markets.

Foreign investment screening

Examine national-security restrictions and foreign-investment approval requirements.

Intellectual property due diligence

Investigate patents, technology licences, research agreements and ownership of biological inventions.

Data protection assessment

Examine genetic databases, personal information, consent arrangements and cross-border transfers.

Biosafety and pharmaceutical compliance

Review GMO licences, clinical trials, manufacturing approvals and therapeutic-product authorisations.

Corporate and financial approvals

Obtain necessary shareholder, court or tribunal, corporate and foreign-exchange approvals.

Regulatory clearance and completion

Complete the transaction only after satisfying applicable approval and standstill requirements.

Post-merger monitoring

Monitor licensing commitments, research independence, biosafety, data security and competition remedies.

11. Remedies available to regulatory authorities

Regulatory authorities have several options when a proposed merger raises legal concerns.

The Bayer/Monsanto and Dow/DuPont decisions illustrate the importance of structural remedies, while Illumina/GRAIL demonstrates the importance of jurisdictional limits on regulatory intervention.

12. Liability for violations of cross-border merger laws

A biotechnology company may face different categories of legal liability.

1. Competition liability

Failure to notify a notifiable combination.

Gun-jumping.

Abuse of dominant position.

Breach of merger commitments.

Anti-competitive licensing practices.

2. Foreign investment liability

Unauthorised foreign investment.

Breach of sectoral conditions.

Incorrect reporting.

Unlawful transfer of securities or assets.

3. Data protection liability

Unlawful transfer of genetic information.

Processing without an appropriate legal basis.

Failure to maintain required security safeguards.

Unauthorised disclosure of confidential research data.

4. Biosafety liability

Failure to maintain containment standards.

Unauthorised transfer of biological materials.

Violation of GMO permissions.

Environmental contamination.

5. Corporate and contractual liability

Breach of acquisition agreements.

Misrepresentation of research assets.

Concealment of regulatory investigations.

Patent ownership disputes.

Failure to disclose clinical-trial liabilities.

13. Comparative analysis of major jurisdictions

14. Challenges in regulating cross-border biotechnology mergers

Several difficulties continue to affect the international regulatory system.

1. Regulatory fragmentation: Different countries apply different definitions, thresholds and approval procedures.

2. Innovation-based valuation: Biotechnology companies may have significant scientific value despite limited turnover.

3. Jurisdictional conflicts: Several regulators may claim authority over the same international acquisition.

4. Genetic-data sovereignty: Countries differ in their treatment of genetic information and international data transfers.

5. Patent concentration: Large acquisitions may consolidate control over essential research technologies.

6. Scientific uncertainty: Regulators may struggle to evaluate future biotechnology markets and emerging research platforms.

7. National-security concerns: Foreign investment screening can conflict with international commercial interests.

8. Regulatory delay: Multiple approval procedures can delay clinical development, manufacturing expansion and research collaboration.

9. Effective remedies: Divestiture of a biotechnology business may be ineffective if the buyer cannot reproduce its research capabilities, specialised workforce or manufacturing infrastructure.

15. Suggestions for legal and regulatory reform

The following reforms could improve the governance of international biotechnology mergers:

Develop stronger international cooperation among competition authorities.

Establish specialised merger-assessment procedures for biotechnology innovation markets.

Improve scrutiny of acquisitions involving genomic databases.

Develop clearer standards for valuing biotechnology intellectual property.

Strengthen foreign investment screening for genuinely sensitive biological technologies.

Introduce effective mechanisms for protecting clinical-trial participants during corporate restructuring.

Improve coordination between competition, pharmaceutical and biosafety regulators.

Develop transparent rules for transferring biological resources across borders.

Strengthen post-merger monitoring of research and development commitments.

Establish appropriate safeguards against excessive concentration of essential gene-editing and diagnostic technologies.

16. Important legal principles emerging from the case laws

These decisions demonstrate that biotechnology mergers cannot be evaluated exclusively through traditional financial indicators. Regulators must also consider control over technology, research capabilities, essential inputs, innovation pipelines and future competition.

17. Conclusion

Cross-Border Biotech Mergers Regulation is an important part of modern international commercial, competition, pharmaceutical and biotechnology law.

Its principal purpose is to balance commercial freedom and international investment with competition, scientific innovation, national security, public health, genetic privacy and environmental protection.

India's Competition Act, 2002, FEMA framework, European Union Merger Regulation, United States antitrust laws and Australia's competition and foreign-investment frameworks collectively demonstrate the complexity of this regulatory area.

The Illumina/GRAIL litigation establishes the importance of jurisdictional limits, while Bayer/Monsanto demonstrates how competition authorities can use divestiture and licensing remedies to protect biotechnology markets.

Ultimately, an effective legal framework must ensure that international biotechnology mergers promote scientific advancement without creating unacceptable concentrations of technological, biological, economic or regulatory power.

18. Important legislation and authorities for further legal research

India

Competition Act, 2002.

Competition (Amendment) Act, 2023.

Competition Commission of India (Combinations) Regulations, 2024.

FEMA, 1999.

FEMA (Cross Border Merger) Regulations, 2018.

Companies Act, 2013.

Biological Diversity Act, 2002.

Patents Act, 1970.

International

EU Merger Regulation 139/2004.

Clayton Act, 1914.

Hart-Scott-Rodino Act, 1976.

Australian Competition and Consumer Act 2010.

Foreign Acquisitions and Takeovers Act 1975 (Australia).

Cartagena Protocol on Biosafety.

Nagoya Protocol.

TRIPS Agreement.

Key authorities: Competition Commission of India, European Commission, US Federal Trade Commission, US Department of Justice, CFIUS, Australian Competition and Consumer Commission and Foreign Investment Review Board.

Academic note: The cases discussed are merger-control and competition precedents with direct or significant relevance to biotechnology transactions. Not every case establishes a general rule governing all forms of biotech acquisition. The applicable statutory provisions, thresholds, exemptions and approval requirements must be checked for the transaction date and the jurisdictions concerned.